Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries.
Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries.
复制标题
DOI：
10.1245/s10434-021-10639-1
复制
发表时间：
2021-10
影响因子：
3.7
通讯作者：
Boughey JC
中科院分区：
文献类型：
--
作者：
Wilke LG;Nguyen TT;Yang Q;Hanlon BM;Wagner KA;Strickland P;Brown E;Dietz JR;Boughey JC
2019年冠状病毒病(新冠肺炎)大流行导致了乳腺癌护理的快速和区域不同的方法。为了评估这些变化，美国乳房外科医生学会(ASBRS)内部开发了一个新冠肺炎专用注册表，跟踪新冠肺炎的决定是正常的还是修改的。回顾了2020年3月1日至2021年3月15日期间输入新冠肺炎专用登记处和ASBRAS MASTY登记处的患者护理数据。总体而言，177名外科医生输入了2791名患者的人口统计和治疗数据。患者平均年龄62.7岁，其中9.0%(252)为非裔美国人。6.2%(173)的患者通过远程医疗进行初始会诊，1.4%(40)的患者发展为新冠肺炎。浸润性肿瘤的平均大小为2.1 cm，17.8%(411)为结节阳性。在雌激素受体阳性/人表皮生长因子受体2阴性(ER+/HER2−)的疾病中，6.9%(119例)的患者通常使用新辅助内分泌治疗(NET)，另外31%(542例)的患者因新冠肺炎而使用新辅助内分泌治疗。随着年龄的增长和居住在东北部或东南部，患者更有可能因新冠肺炎而接受NET治疗(优势比[OR]分别为1.1、2.3和1.7；p <； 0.05)。51.5%(781例)的雌激素阳性患者进行了基因组检测，其中20.7%(162例)的患者因新冠肺炎而进行了核心检测。年龄较大的患者因新冠肺炎而接受核心活检基因组检测的可能性较低(OR0.89；p = 0.01)，而淋巴结阳性患者更有可能接受核心活检基因组检测(OR4.0；p <； 0.05)。据报道，有5.4%(151)的患者因新冠肺炎而改变了手术方式。ASBRS新冠肺炎登记处提供了一个监测因大流行而引起的治疗变化的平台，突出了NET的使用增加。
The coronavirus disease 2019 (COVID-19) pandemic has resulted in rapid and regionally different approaches to breast cancer care. In order to evaluate these changes, a COVID-19-specific registry was developed within the American Society of Breast Surgeons (ASBrS) Mastery that tracked whether decisions were usual or modified for COVID-19. Data on patient care entered into the COVID-19-specific registry and the ASBrS Mastery registry from 1 March 2020 to 15 March 2021 were reviewed. Overall, 177 surgeons entered demographic and treatment data on 2791 patients. Mean patient age was 62.7 years and 9.0% (252) were of African American race. Initial consultation occurred via telehealth in 6.2% (173) of patients and 1.4% (40) developed COVID-19. Mean invasive tumor size was 2.1 cm and 17.8% (411) were node-positive. In estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) disease, neoadjuvant endocrine therapy (NET) was used as the usual approach in 6.9% (119) of patients and due to COVID-19 in an additional 31% (542) of patients. Patients were more likely to receive NET due to COVID-19 with increasing age and if they lived in the Northeast or Southeast (odds ratio [OR] 1.1, 2.3, and 1.7, respectively; p < 0.05). Genomic testing was performed on 51.5% (781) of estrogen-positive patients, of whom 20.7% (162) had testing on the core due to COVID-19. Patients were less likely to have core biopsy genomic testing due to COVID-19 if they were older (OR 0.89; p = 0.01) and more likely if they were node-positive (OR 4.0; p < 0.05). A change in surgical approach due to COVID-19 was reported for 5.4% (151) of patients. The ASBrS COVID-19 registry provided a platform for monitoring treatment changes due to the pandemic, highlighting the increased use of NET.
登录
查看更多内容
影响因子：
6.2
作者：
Nyante SJ;Benefield TS;Kuzmiak CM;Earnhardt K;Pritchard M;Henderson LM
通讯作者：
Henderson LM
影响因子：
3.7
作者：
Chiba A;Hoskin TL;Heins CN;Hunt KK;Habermann EB;Boughey JC
通讯作者：
Boughey JC
影响因子：
45.3
作者：
Marron, Jonathan M.;Joffe, Steven;Hlubocky, Fay J.
通讯作者：
Hlubocky, Fay J.
影响因子：
7.3
作者：
Toss A;Isca C;Venturelli M;Nasso C;Ficarra G;Bellelli V;Armocida C;Barbieri E;Cortesi L;Moscetti L;Piacentini F;Omarini C;Andreotti A;Gambini A;Battista R;Dominici M;Tazzioli G
通讯作者：
Tazzioli G
验证21基因测试是对ER+，HER2阴性乳腺癌的新辅助激素治疗的临床反应的预测指标：Transneos研究。
影响因子：
3.8
作者：
Iwata H;Masuda N;Yamamoto Y;Fujisawa T;Toyama T;Kashiwaba M;Ohtani S;Taira N;Sakai T;Hasegawa Y;Nakamura R;Akabane H;Shibahara Y;Sasano H;Yamaguchi T;Sakamaki K;Bailey H;Cherbavaz DB;Jakubowski DM;Sugiyama N;Chao C;Ohashi Y
通讯作者：
Ohashi Y